| Bioactivity | MTR-106 is a potent and orally active G-quadruplex stabilizer and RNA polymerase I inhibitor. MTR-106 induces apoptosis and inhibits cell growth. MTR-106 can be used in research of cancer[1]. |
| Invitro | MTR-106 (0-100 μM; 7 d) 在 HR 缺陷细胞和 PARPi 耐药细胞中均具有抗肿瘤活性[1]。MTR-106 (0-100 μM; 7 d) 诱导细胞凋亡、细胞周期停滞和 DNA 损伤[1]。 Cell Viability Assay[1] Cell Line: |
| In Vivo | MTR-106 (10-30 mg/kg; 口服; 每周两次, 持续 29 天) 抑制裸鼠中 BRCA 缺陷和 PARPi 抗性异种移植物的肿瘤生长[1]。 Animal Model: |
| Name | MTR-106 |
| CAS | 1639357-93-9 |
| Formula | C28H27N7O2S |
| Molar Mass | 525.62 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li MZ, et, al. Discovery of MTR-106 as a highly potent G-quadruplex stabilizer for treating BRCA-deficient cancers. Invest New Drugs. 2021 Oct;39(5):1213-1221. |